Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to talk about the best 2 stocks to consider

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
02 Oct 2025, 22:12 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to talk about the best  2 stocks to consider
Source overview

AI-generated source summary

The video provides a fundamental analysis of SOFI and AMZN stock. For SOFI, it highlights that is undervalued and the earnings per share should be up 150% going to 2026. Additionally, is getting into crypto again. It has 11.7M members and the addressable market is huge. The speaker uses a 40 PE ratio with the assumption that the price will be $0.8 in 2026, implying upside of 168% to $69.12. The fail price should be around $25. For AMZN, the speaker states that this stock is cheap because they are not giving much attention. The forward price to operating cash flow is 14, below long term average of 19.22. They expect Antropic could add roughly 400 BPS per quarter, It could catch up to the other big six and increase the stock to be around $242.52. The actual trend is bullish.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
50%
2 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    2 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail